Medtronic (NYSE:MDT) Stock Keeps “Buy” Rating at TD Cowen

Medtronic (NYSE:MDT)‘s stock had its “buy” rating reaffirmed by stock analysts at TD Cowen in a report released on Wednesday, MarketBeat.com reports. They presently have a $110.00 price target on the medical technology company’s stock. TD Cowen’s price objective indicates a potential upside of 26.38% from the company’s previous close.

Several other analysts have also recently weighed in on MDT. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Monday, August 10th. Sanford C. Bernstein cut their price objective on Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. JPMorgan Chase & Co. decreased their price objective on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Nineteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $103.92.

Medtronic Stock Down 0.1%

NYSE:MDT traded down $0.05 during trading hours on Wednesday, reaching $87.04. 9,672,962 shares of the stock were exchanged, compared to its average volume of 9,084,351. The firm has a 50 day moving average of $89.91 and a 200 day moving average of $84.79. Medtronic has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The stock has a market cap of $111.33 billion, a PE ratio of 21.45, a PEG ratio of 2.04 and a beta of 0.56.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts expect that Medtronic will post 5.98 earnings per share for the current year.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Medtronic

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Medtronic by 17.4% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 73,993 shares of the medical technology company’s stock worth $5,788,000 after buying an additional 10,960 shares during the last quarter. State Street Corp boosted its position in Medtronic by 2.7% during the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares in the last quarter. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Medtronic in the second quarter valued at approximately $48,000. Wellington Altus USA Inc. grew its holdings in Medtronic by 18.1% during the 2nd quarter. Wellington Altus USA Inc. now owns 2,294 shares of the medical technology company’s stock valued at $199,000 after buying an additional 351 shares during the last quarter. Finally, Bullseye Investment Management LLC acquired a new position in shares of Medtronic in the second quarter valued at approximately $45,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced U.S. FDA clearance and CE Mark approval for its Affera Prism-2 Mapping Software, along with CE Mark approval for the PulseSelect ProxBox Adapter with Proximity Indicator software. The products expand cardiac mapping and real-time tissue-proximity capabilities, potentially strengthening Medtronic’s electrophysiology portfolio and supporting future procedure growth. Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating and set a $110 price target, implying substantial upside from recent trading levels. The call indicates continued confidence in Medtronic’s valuation and business outlook.
• Positive Sentiment: Medtronic is being highlighted by Zacks as a long-term value stock. Its recent earnings report also showed better-than-expected adjusted earnings and revenue growth, providing fundamental support for the value argument. Why Medtronic is a Top Value Stock for the Long-Term
• Neutral Sentiment: Options activity was notably elevated, with investors purchasing 29,587 call options—82% above average volume. This may signal bullish positioning, though options activity alone does not guarantee sustained buying in the shares.
• Neutral Sentiment: Medtronic was included in lists of attractively valued medical-device and dividend-growth stocks. Such coverage reinforces its defensive appeal but is unlikely to materially change near-term fundamentals.
• Negative Sentiment: The stock recently declined more sharply than the broader market, reflecting near-term selling pressure despite the company’s longer-term earnings and product catalysts. Medtronic Registers a Bigger Fall Than the Market

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.